Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 20, Issue 18, 2002, Pages 3885-3890

  Ansell, Stephen M ^a   Ristow, Kay M ^a   Habermann, Thomas M ^a   Wiseman, Gregory A ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; GROWTH FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERABILITY; EVALUATION; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 0037106268     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.143     Document Type: Article

References (21)

1. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes
2. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
3. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation
4. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
5. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
6. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
7. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
8. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
9. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
10. Final results of a randomized controlled study of the Zevalin™ radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
11. Pivotal study of iodine 1 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
12. Some like it hot!
13. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
14. Biodistribution and dosimetry results from a phase 111 prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
15. Nonparametric estimation from incomplete observations
16. Evaluation of survival data and two new rank order statistics arising in its consideration
17. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project
18. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
19. 90Y- labeled anti-CD20 monoclonal antibody
20. High-dose therapy can be safely and successfully administered after Zevalin treatment